Autres langues Beam Therapeutics Inc.

Actions

BEAM

US07373V1052

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
23,13 ^USD	+1,80%		+8,19%	-15,03%

04/04	Un initié de Beam Therapeutics a vendu des actions pour une valeur de 581 617 $, selon un récent dépôt auprès de la SEC	MT
04/04	Un initié de Beam Therapeutics a vendu des actions pour une valeur de 734 805 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	04/04
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	04/04
Beam Therapeutics Says BEAM-302 Drug Candidate Gets UK Clearance for Alpha-1 Antitrypsin Deficiency	26/03
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	26/03
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	26/03
Beam Therapeutics Inc. Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency	26/03
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	28/02
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	28/02
Health Care Down as Viking Move Rattles Novo Shares -- Health Care Roundup	27/02
Beam Therapeutics Shares Jump on Surprise Q4 Profit	27/02
Beam Therapeutics Reports Surprise Q4 Profit; Shares Jump in Early Trading	27/02
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones	27/02
Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	05/02
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	05/02
Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto	30/01
North American Morning Briefing : Microsoft Kicks -2-	30/01
Beam Therapeutics Shares Gain Following JPMorgan's Upgrade to Overweight	29/01
Rapport Therapeutics Appoints Terry-Ann Burrell to Board of Directors	17/01
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones	08/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Andy Bromberg, PDG de Beam : Les ETF Bitcoin, une financiarisation éloignée de l'essence originelle de la crypto

Le 30 janvier 2024 à 20:21